JNJNYSE

Johnson & Johnson

Healthcare· Drug Manufacturers - General

www.jnj.com

Earnings2026-10-13in 3mo

$265.95

+$2.55(+0.97%)today

Market Cap640.91B

Key Statistics

52-Week Range

$164.23

$269.43

Current $265.95 · 97% of range

Prev. Close$263.40

Day's High$268.77

Day's Low$261.35

Volume5.77MAvg 8.23M

P/E (TTM)30.57Fwd 20.73

EPS (TTM)$8.70

Div. Yield2.03%$5.36/share

Beta0.23

50D Avg$242.64

200D Avg$225.02

Short % Float1.3%3.0 days to cover

Shares Short27.43M

Price Performance

JNJ

S&P 500

normalized to 0% at period start

Latest News

10 articles

Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims

MT Newswires

42m ago

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Insider Monkey

13h ago

JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc Litigation

Stocktwits

10h ago

President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling

Insider Monkey

20h ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Business Wire

11h ago

Johnson & Johnson offers $5.5 billion to settle talc lawsuits

CBS News

3h ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

The Wall Street Journal

8h ago

J&J reaches sweeping talc deal that could end decade of litigation

Reuters

2h ago

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Zacks

18h ago

Why Chasing a 9% Yield Could Cost You $200,000 in Retirement Income

24/7 Wall St.

9h ago

About

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases…

Quarter	EPS Est.	EPS Actual	Surprise	Revenue Est.	Revenue Actual
Q2 2026 2026-06-30	$2.85	$2.90	+1.6%	—	25.31B
Q1 2026 2026-03-31	$2.68	$2.70	+0.9%	—	24.06B
Q4 2025 2025-12-31	$2.46	$2.46	-0.1%	—	24.56B
Q3 2025 2025-09-30	$2.76	$2.80	+1.5%	—	23.99B

Financials

Full Statements

Income

Revenue (TTM)97.93B

Revenue Growth (YoY)+6.60%

Gross Profit66.73B

Gross Margin+68.1%

Operating Margin+29.2%

Net Margin+21.5%

EBITDA34.87B

Free Cash Flow16.89B

Earnings Growth (YoY)-0.90%

Balance & Valuation

Total Cash20.76B

Total Debt49.04B

Debt/Equity57.71

Return on Equity+25.7%

Return on Assets+8.6%

Price / Book7.54

Price / Sales6.54

Enterprise Value669.19B

EPS (Forward)$12.83

Book Value / Share$35.28

Analyst Ratings

23 analysts · 0m

Strong Buy70% bullish

Strong Buy

Buy

Hold

Sell

Strong Sell

Price Target

$274.00+3.0% upside

High: $305.00

Low: $190.00

Trend

70% buy

-1m

65% buy

-2m

63% buy

Distributions

2.03% yield

Annual Rate$5.36/share

Last Payment$1.3400/share

FrequencyQuarterly

Yield2.03%

Trailing Yield1.99%

5Y Avg Yield2.77%

Payout Ratio60.8%

Ex-Dividend Date2026-08-25in 28d

Pay Date2026-09-08in 42d

Last Pay Date

Institutional Ownership

5,733 holders

Institutional

76.8%

Insider

0.0%

1Blackrock Inc.

213.39M sh

8.85%

2Vanguard Capital Management LLC

156.61M sh

6.50%

3State Street Corporation

133.48M sh

5.54%

4Vanguard Portfolio Management LLC

Insider Activity

Last 90 days

Buys

10 txns

56.19M

Sells

0 txns

BROADHURST VANESSA

Officer

+23K shares

5.79M

2026-07-20

WENGEL KATHRYN E

Chief Technology Officer

+10K shares

2.41M

2026-06-11

REED JOHN C

Officer

+25K shares

2026-05-01

10-K Risk Factors

SEC Filings

Date	Amount
2026-05-26	$1.3400
2026-02-24	$1.3000
2025-11-25	$1.3000
2025-08-26	$1.3000
2025-05-27	$1.3000
2025-02-18	$1.2400
2024-11-26	$1.2400
2024-08-27	$1.2400